Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07431853 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About mRNA Vaccines Against Influenza in Adults
A Phase 2 study of Healthy Adults, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 770
- Enrollment target
- 15
- Study locations
NCT07431853 is a Phase 2 study of Healthy Adults that is actively recruiting participants, run by Pfizer. The registered enrollment target is 770 participants, above the 63-participant average among 33 other Healthy Adults trials with a reported enrollment target (1122% higher). The trial reports 15 study locations across 13 states.
The verdict
NCT07431853, a Phase 2 study of Healthy Adults, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 770 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison. Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.
Conditions Studied
Interventions
- BIOLOGICAL Vaccine Candidate #1
- BIOLOGICAL Vaccine Candidate #2
- BIOLOGICAL Vaccine Candidate #3
- BIOLOGICAL Vaccine Candidate #4
- BIOLOGICAL Vaccine Candidate #5
Study Locations (15)
Florida
- Indago Research & Health Center, Inc - Hialeah
- Palm Springs Community Health Center - Miami Lakes
Texas
- SMS Clinical Research LLC - Mesquite
- DM Clinical Research - Tomball
Alabama
- AMR Clinical - Mobile
California
- Diablo Clinical Research, LLC d/b/a Flourish Research - Walnut Creek
Connecticut
- Clinical Research Consulting, LLC - Milford
District of Columbia
- George Washington Medical Faculty Associates - Washington D.C.
Georgia
- Clinical Research Atlanta - Stockbridge
Hawaii
- East-West Medical Research Institute - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2027-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07431853
The ClinicalTrials.gov registry entry for NCT07431853 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 770 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 33 other Healthy Adults trials with a reported enrollment target (1122% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 5 interventions - of which Vaccine Candidate #1 is the first listed.
NCT07431853 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Florida, Texas, Alabama.
Frequently Asked Questions
What is clinical trial NCT07431853 about?
NCT07431853 is a clinical study titled "A Study to Learn About mRNA Vaccines Against Influenza in Adults". The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older...
What is the current status of trial NCT07431853?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 770 participants. The study started on 2026-02-23. Estimated completion is 2027-06-22.
What conditions does trial NCT07431853 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT07431853?
The interventions under investigation include: Vaccine Candidate #1 (BIOLOGICAL), Vaccine Candidate #2 (BIOLOGICAL), Vaccine Candidate #3 (BIOLOGICAL), Vaccine Candidate #4 (BIOLOGICAL), Vaccine Candidate #5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07431853?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07431853 being conducted?
This trial has 15 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Breathing Training and Nitrate on Exercise at Simulated Altitude
RECRUITING · NA
-
Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines
RECRUITING · NA
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
RECRUITING · Phase 1
-
Health Properties of Pecan Nut Consumption
RECRUITING · NA
-
The Brain Processes Underlying Speech Motor Learning and Speech Production
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.